RPL35P8: A Potential Drug Target and Biomarker for ALS-Related Neuronal Degeneration

Target Name: RPL35P8

NCBI ID: G643653

RPL35P8

Other Name(s): Ribosomal protein L35 pseudogene 8 | RPL35_6_1759 | ribosomal protein L35 pseudogene 8

RPL35P8: A Potential Drug Target and Biomarker for ALS-Related Neuronal Degeneration

Introduction

Ribosomal protein L35 (RPL35) is a key protein that forms the basis of the Ribosomal System (RS), a complex protein machinery that synthesizes proteins in the cell. TheRS is a crucial component of cellular quality control, and it plays a vital role in the synthesis of proteins involved in various cellular processes. One of the proteins synthesized by the RS is Ribosomal protein L35 (RPL35), which is known to be involved in the regulation of protein synthesis and stability.

In amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects approximately 46 million people worldwide, the loss of motor neurons and the progressive degeneration of the central nervous system have been observed. The exact cause of ALS is not known, but it is often associated with the presence of neurofibrillary tangles and protein aggregates in the brain.

Recent studies have identified several potential drug targets and biomarkers for ALS, and one of them is RPL35P8, a pseudogene encoding the protein RPL35. RPL35P8 has been shown to be involved in the regulation of protein synthesis and stability, and it has been proposed as a potential drug target in the treatment of ALS.

Potential Drug Target: RPL35P8

RPL35P8 is a 21-kDa protein that is synthesized by the RS and has been shown to play a role in the regulation of protein synthesis and stability. It is composed of a unique N-terminus and a C-terminus that contain a conserved ATP- binding site and a GTP-binding site, respectively. The N-terminus of RPL35P8 contains a 25 amino acid residue that is involved in the interaction with ATP and GTP.

Several studies have shown that RPL35P8 is involved in the regulation of protein synthesis and stability, including the regulation of microtubule dynamics and the stability of protein aggregates. It has been proposed that RPL35P8 may play a role in the pathogenesis of ALS by contributing to the neurofibrillary tangles and protein aggregates that are observed in the brain.

Biomarker: RPL35P8

RPL35P8 has also been suggested as a potential biomarker for ALS. The presence of RPL35P8 in the brain has been observed in autopsy cases of ALS patients, and it has been used as a marker for the diagnosis of ALS. Additionally, levels of RPL35P8 have been shown to be elevated in the spinal cord of ALS patients, which may indicate a potential therapeutic target for the disease.

The childhood multiple sclerosis (ALS) is a progressive neurological disease characterized by motor neuron loss and progressive neurological degeneration. Currently, there are no definite drugs or biomarkers for the treatment of ALS. However, some studies have shown that RPL35P8, a protein related to RS, may be a potential drug target or biomarker for the treatment of ALS.

RPL35P8 is a 21-kDa protein synthesized by RS. It consists of a unique N-terminus and a C-terminus, containing an ATP-binding site and a GTP-binding site respectively. The N-terminus contains a 25-amino acid residue that binds ATP and GTP. Several studies have shown that RPL35P8 is involved in regulating protein synthesis and stability, including regulating microtubule dynamics and the stability of protein aggregation. Therefore, RPL35P8 may be involved in the pathogenesis of ALS and may also be a potential drug target or biomarker for the treatment of ALS.

Protein Name: Ribosomal Protein L35 Pseudogene 8

The "RPL35P8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL35P8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets